Keep those masks handy and vaccines up to date:
https://www.medpagetoday.com/meetingcoverage/ccc/108524
https://www.medpagetoday.com/meetingcoverage/ccc/108524
History of IBD Linked to Severe Outcomes in Patients Hospitalized for COVID
- Thread starter Scipio
- Start date
Help Support Crohn's Disease Forum:
- Joined
- Apr 15, 2012
- Messages
- 14,752
I think they need to study meds taken during ibd as factor as well .
Some biologics are used to treat sepsis (IL-1)
So…. That might be an important factor for some
Some biologics are used to treat sepsis (IL-1)
So…. That might be an important factor for some
ibd = low bifids = bad covid outcomes
it's been found that the bioweapons target/destory the bifid bugs in our guts. some researchers say they can predict covid outcome based on the number of bifid bugs alone. this is also the cause of so-called long covid. the bifid bugs have been decimated, doing much harm to the immune system. seeing all sorts of diseases rise because of this -- autoimmunes, turbo cancer, more.
the best defense against their bioweapons is gut health, esp the all-important bifid family of bacteria.
masks -- more harm than good. zero efficacy and negative side effects
injections -- more harm than good. short term efficacy (maybe, if lucky) and horrific long term side effects, esp to the immune system
it's been found that the bioweapons target/destory the bifid bugs in our guts. some researchers say they can predict covid outcome based on the number of bifid bugs alone. this is also the cause of so-called long covid. the bifid bugs have been decimated, doing much harm to the immune system. seeing all sorts of diseases rise because of this -- autoimmunes, turbo cancer, more.
the best defense against their bioweapons is gut health, esp the all-important bifid family of bacteria.
masks -- more harm than good. zero efficacy and negative side effects
injections -- more harm than good. short term efficacy (maybe, if lucky) and horrific long term side effects, esp to the immune system
Last edited:
https://www.managedhealthcareexecutive.com/view/the-path-to-shortening-long-covid-may-go-through-gut
For reasons that aren’t entirely clear, long COVID is associated with diminished microbial diversity in the gut and a decrease in several healthful strains of bacteria, such as Bifidobacterium adolescentis. Researchers are now exploring whether therapies that aimed at reviving a beleaguered gut microbiome’s profile might be an avenue for treating long COVID.
Last week researchers at The Chinese University of Hong Kong reported positive results for microbiome-modifying therapy in the journal The Lancet Infectious Diseases. Although randomized and double blinded, the study was conducted at a single center and so must be interpreted with some caution.
Long COVID is also called long-haul COVID, post-COVID-19 conditions and chronic COVID. The technical term is post-acute sequelae of SARS-CoV-2 (PASC). Some research suggests that the proportion of people who develop long COVID after the initial infection has decreased. The National Center for Health Statistics reported in September 2023 that 6.9% of those who have had COVID-19 had had long COVID, according to the 2022 National Health Interview Survey.
Joint first authors Raphaela I. Lau, Ph.D., and Qi Su and colleagues tested a preparation that included three strains of bacteria — Bifidobacterium adolescentis, Bifidobacterium bifidum and Bifidobacterium longum — and three compounds that encourage the growth of healthful bacteria: galacto-oligosaccharides, xylo-oligosaccharides and resistant dextrin. The study subjects were people had at least one of 14 long COVID symptoms for four weeks or more after a confirmed infection with SARS-CoV-2 (the virus that causes COVID-19) by either a PCR test or a rapid antigen test. Between June 2021 and August 2022, the researchers randomly assigned 463 patients to either take a placebo (vitamin C) twice daily or the bacteria-prebiotic preparation. The primary end point was the alleviation of long COVID symptoms by six months; alleviation was defined as a reduction in the severity of symptoms leading to an improvement The symptoms were measured by responses to a questionnaire commonly used in the research long COVID symptoms. After drop outs, withdrawals and loss to follow-up, the study had 204 people in the treatment group and 199 in the placebo group.
Results reported by Lau and Su and colleagues showed that those assigned to the treatment group fared than those assigned to the placebo group on all 14 long COVID symptoms.
For reasons that aren’t entirely clear, long COVID is associated with diminished microbial diversity in the gut and a decrease in several healthful strains of bacteria, such as Bifidobacterium adolescentis. Researchers are now exploring whether therapies that aimed at reviving a beleaguered gut microbiome’s profile might be an avenue for treating long COVID.
Last week researchers at The Chinese University of Hong Kong reported positive results for microbiome-modifying therapy in the journal The Lancet Infectious Diseases. Although randomized and double blinded, the study was conducted at a single center and so must be interpreted with some caution.
Long COVID is also called long-haul COVID, post-COVID-19 conditions and chronic COVID. The technical term is post-acute sequelae of SARS-CoV-2 (PASC). Some research suggests that the proportion of people who develop long COVID after the initial infection has decreased. The National Center for Health Statistics reported in September 2023 that 6.9% of those who have had COVID-19 had had long COVID, according to the 2022 National Health Interview Survey.
Joint first authors Raphaela I. Lau, Ph.D., and Qi Su and colleagues tested a preparation that included three strains of bacteria — Bifidobacterium adolescentis, Bifidobacterium bifidum and Bifidobacterium longum — and three compounds that encourage the growth of healthful bacteria: galacto-oligosaccharides, xylo-oligosaccharides and resistant dextrin. The study subjects were people had at least one of 14 long COVID symptoms for four weeks or more after a confirmed infection with SARS-CoV-2 (the virus that causes COVID-19) by either a PCR test or a rapid antigen test. Between June 2021 and August 2022, the researchers randomly assigned 463 patients to either take a placebo (vitamin C) twice daily or the bacteria-prebiotic preparation. The primary end point was the alleviation of long COVID symptoms by six months; alleviation was defined as a reduction in the severity of symptoms leading to an improvement The symptoms were measured by responses to a questionnaire commonly used in the research long COVID symptoms. After drop outs, withdrawals and loss to follow-up, the study had 204 people in the treatment group and 199 in the placebo group.
Results reported by Lau and Su and colleagues showed that those assigned to the treatment group fared than those assigned to the placebo group on all 14 long COVID symptoms.
https://pubmed.ncbi.nlm.nih.gov/38257958/
COVID-19 has been associated with having a negative impact on patients' gut microbiome during both active disease and in the post-acute phase. In acute COVID-19, rapid alteration of the gut microbiome composition was observed, showing on one side a reduction in beneficial symbionts (e.g., Roseburia, Lachnospiraceae) and on the other side an increase in opportunistic pathogens such as Enterococcus and Proteobacteria.
Alpha diversity tends to decrease, especially initially with symptom onset and hospital admission. Although clinical recovery appears to align with improved gut homeostasis, this process could take several weeks, even in mild infections. Moreover, patients with COVID-19 post-acute syndrome showed changes in gut microbiome composition, with specific signatures associated with decreased respiratory function up to 12 months following acute disease.
COVID-19 has been associated with having a negative impact on patients' gut microbiome during both active disease and in the post-acute phase. In acute COVID-19, rapid alteration of the gut microbiome composition was observed, showing on one side a reduction in beneficial symbionts (e.g., Roseburia, Lachnospiraceae) and on the other side an increase in opportunistic pathogens such as Enterococcus and Proteobacteria.
Alpha diversity tends to decrease, especially initially with symptom onset and hospital admission. Although clinical recovery appears to align with improved gut homeostasis, this process could take several weeks, even in mild infections. Moreover, patients with COVID-19 post-acute syndrome showed changes in gut microbiome composition, with specific signatures associated with decreased respiratory function up to 12 months following acute disease.
Similar threads
